Quality & complianceOfficial

DKMA flags Xylocain 20 mg/g gel supply problems running to end of March 2027

🇩🇰 DKMA · Fri 06 Nov 2026

Denmark's medicines agency says Aspen Nordic is struggling to deliver the lidocaine gel, with disruption expected from mid-July 2026 until the end of March 2027.

The Danish Medicines Agency (DKMA) has published a supply notice for Xylocain 20 mg/g gel, reporting current problems with deliveries from Aspen Nordic, a branch of Aspen Pharma Ireland Limited in Ireland. The notice was first posted on 29 June 2026 and last updated on 6 November 2026.

The product contains the active substance lidocaine, as lidocaine hydrochloride monohydrate, and carries the ATC code N01BB02. DKMA gives the expected period of disruption as mid-July 2026 to the end of March 2027, which is a stretch of roughly eight months.

The agency states the cause as delivery difficulties and does not elaborate. The notice does not name alternative products, describe any mitigation measures or say whether specific pack sizes are affected. DKMA directs questions about the current status to the company rather than to the agency.

As background, DKMA publishes such notices in its section on medicine supply announcements, alongside its wider material on shortages, foreign alternatives and reporting of supply difficulties.

What it means for your team

  • Supply-chain and market-access teams in Denmark should plan for possible limited availability of Xylocain 20 mg/g gel until at least the end of March 2027.
  • The notice names no alternatives, so teams needing substitutes should consult DKMA's pages on supply notices and foreign alternatives, and not assume a replacement.
  • Questions about current stock should go to Aspen Nordic, as DKMA directs, since the agency gives no detail beyond the expected period and the stated cause.
  • Check the DKMA notice periodically, as it has already been updated since its first publication in June.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →